world
FDA Grants Fast-Track Voucher to Partner Therapeutics for Bile Duct Cancer Therapy
The US FDA has awarded a new fast-track voucher to Partner Therapeutics for its bile duct cancer drug. The designation is intended to expedite regulatory review of the treatment. It marks the latest use of the agency's voucher program for therapies targeting rare or serious conditions.
May 6, 5:15 PM·1m read1 source
fda.govAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The US FDA granted a new fast-track voucher to Partner Therapeutics' bile duct cancer drug, according to @Reuters reported. The voucher is a fast-track voucher designed to accelerate development and review processes for medicines addressing serious diseases with unmet medical needs.
The regulatory body involved is the US FDA, which issued the designation for the bile duct cancer treatment developed by Partner Therapeutics.
The drug is described as Partner Therapeutics' bile duct cancer drug, a therapy aimed at a form of cancer that affects the bile ducts and often carries a challenging prognosis. Receipt of the voucher provides Partner Therapeutics with benefits that can include more frequent interactions with FDA reviewers and a shortened review timeline upon submission of a marketing application.
This latest award continues the FDA's use of the fast-track voucher mechanism to incentivize development in oncology areas where treatment options remain limited.
The designation applies specifically to Partner Therapeutics' bile duct cancer drug and does not extend to other products in the company's portfolio.
